Lantus (insulin glargine) / Sanofi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

12 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lantus (insulin glargine) / Sanofi
2006-000247-26: A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargine

 
3
60
Europe
Human Insulin Inhalation Powder (HIIP), LY041001, Lantus 100I.U/ml solution for injection in a vial, Lantus 100I.U/ml solution for injection in a cartridge, Lantus 100I.U/ml solution for injection in a cartridge for OptiClik, Lantus 100I.U/ml OptiSet solution for injection, Lantus 100I.U/ml solution for injection in a vial, Lantus 100I.U/ml solution for injection in a cartridge, Lantus 100I.U/ml solution for injection in a cartridge for OptiClik, Lantus 100I.U/ml OptiSet solution for injection
Eli Lilly and Company Ltd, Lilly S.A.
Male or female nonsmoking patients 18 years of age or older; have had type 2 diabetes mellitus for at least 6 months at study entry and have been treated with one or more oral antihyperglycemic medications on a stable dose for at least 6 weeks (3 months for thiazolidinediones [TZDs]) and once-daily insulin glargine for at least 4 months, have FEV1 and DLCO >70% predicted, and have an HbA1c between 7.5% and 9.5% at screening.
 
05/08
2006-000305-35: A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Ongoing
3
55
Europe
Technosphere®/Insulin, Lantus 100 IU/ml, NovoMix 30 Penfill 100 U/ml, Lantus 100 IU/ml, NovoMix Penfill 100 U/ml, Lantus 100 IU/ml, NovoMix Penfill 100 U/ml
MannKind Corporation
Diabetes mellitus type II
 
 
2006-000306-23: A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Basal Insulin and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow-up

Ongoing
3
30
Europe
Technosphere®/Insulin, Lantus 100 IU/ml, NovoRapid 100 U/ml, Lantus 100 IU/ml, NovoRapid 100 U/ml, Lantus 100 IU/ml, NovoRapid 100 U/ml
MannKind Corporation
Diabetes mellitus type I
 
 
2010-023792-25: A randomised controlled trial of continuous subcutaneous insulin infusion(CSII) compared to multiple daily injection(MDI) regimens on insulin in children and young people at diagnosis of type I diabetes mellitus (TIDM).

Ongoing
3
316
Europe
Insulin Glargine, Insulin Aspart, Lantus 100 units/ml solution for injection in a cartridge Lantus 100 units/ml solution for injection in a pre-filled pen(optiset), NovoRapid 100 U/ml solution for injection in vial. NovoRapid Penfill 100 U/ml solution for injection in cartridge. NovoRapid Flexpen 100 U/ml solution for injection in prefilled pen., Lantus 100 units/ml solution for injection in a cartridge Lantus 100 units/ml solution for injection in a pre-filled pen(optiset), NovoRapid 100 U/ml solution for injection in vial. NovoRapid Penfill 100 U/ml solution for injection in cartridge. NovoRapid Flexpen 100 U/ml solution for injection in prefilled pen.
Alder Hey Children\'s NHS Foundation Trust
Type 1 Diabetes Mellitus
 
 
2014-003298-40: STUDY OF THE EFFICACY AND SAFETY OF LIRAGLUTIDE IN TYPE 2 DIABETIC PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROME. IMPACT ON CARDIOVASCULAR RISK FACTOR. ESTUDIO DE LA EFICACIA Y SEGURIDAD DE LIRAGLUTIDA EN EL PACIENTE DIABÉTICO TIPO 2 HOSPITALIZADO CON SÍNDROME CORONARIO AGUDO. IMPACTO SOBRE FACTOR DE RIESGO CARDIOVASCULAR.

Ongoing
3
80
Europe
liraglutide, glargine insulin, VICTOZA, LANTUS, VICTOZA, LANTUS
Instituto de Investigación La Fe, Instituto de Investigación Sanitaria La Fe
TYPE 2 DIABETIC HOSPITALIZED PATIENTS WITH ACUTE CORONARY SYNDROME. PACIENTE DIABÉTICO TIPO 2 HOSPITALIZADO CON SÍNDROME CORONARIO AGUDO.
 
 
2015-002135-17: Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes. Efficacia clinica, farmacocinetica, farmacodinamica e variabilit¿ intra-soggetto dell¿analogo dell¿insulina ad azione ritardo Glargine U300 vs Glargine U100 nel Diabete Mellito Tipo 1

Ongoing
3
62
Europe
insulina glargine, na, Concentrate for solution for injection, Toujeo, LANTUS - 100 U/ML SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - CARTUCCIA(VETRO) IN PENNA PRE-RIEMPITA (SOLOSTAR)3 ML 6 PENNE PRERIEMPITE
UNIVERSITà DEGLI STUDI DI PERUGIA, Fondi di ricerca e collaborazioni farmaceutiche
Type 1 Diabetes Mellitus Diabete Mellito tipo 1, Type 1 Diabetes Mellitus Diabete Mellito tipo 1, Diseases [C] - Hormonal diseases [C19]
 
 
2010-022246-25: Diagnostic clinique et mécanismes physiopathologiques de l'allergie à l'insuline.

Not yet recruiting
3
70
Europe
Actrapid, Insulatard, Insuman Infusat, Humalog, NovoRapid, Apidra, Lantus, Levemir, Latex, Solution for injection, Suspension for injection, Solution for infusion, Actrapid, Insulatard, Novorapid, Levemir
Allergie à l'insuline
 
 
2016-001401-16: The SUGAR-DIP trial: Oral medication versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie versus insuline voor zwangerschapsdiabetes

Ongoing
3
810
Europe
Metformin, Glibenclamide, Tablet, Injection, Metformin, Glibenclamide, Insulin: including - fast acting, analog: NovoRapid, Humalog, Apidra - short acting, human: Actrapid, Humuline Regular, Insuman Rapid - medium long acting, human: Insulatard, Humuline NPH, Insuman Basal - long acting analog: Lantus, Levemir
University Medical Center Utrecht, ZonMw
The medical condition to be investigated in this trial is gestational diabetes with insufficient glycemic control by means of dietary adjustments and thus an indication for addiotional pharmacological treatment. In deze trial wordt het ziektebeeld diabetes gravidarum onderzocht, waarbij er met dieetaanpassingen onvoldoende glucosecontrole is bereikt en er dus indicatie is voor aanvullende farmacologische behandeling., Gestational diabetes, also known as gestational diabetes mellitus, is a condition in which women without previously diagnosed diabetes exhibit high blood glucose (blood sugar) levels during pregnancy. Zwangerschapssuikerziekte, ook wel zwangerschapsdiabetes, is een aandoening waarbij vrouwen waarbij niet al eerder suikerziekte is vastgesteld, tijdens de zwangerschap hoge bloedsuikerwaardes hebben., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
2020-005309-18: A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3) Klinikai vizsgálat annak tanulmányozására, hogy az IcoSema, az ikodek inzulin és a szemaglutid kombinációjából álló, hetente alkalmazott új gyógyszer mennyire kontrollálja jól a 2-es típusú cukorbetegek vércukorszintjét a naponta, aszpart inzulinnal együtt alkalmazott glargin inzulinnal összehasonlítva (COMBINE 3)

Ongoing
3
680
Europe
IcoSema 700 U/mL + 2 mg/mL PDS290, Solution for injection in pre-filled pen, Solution for injection, Lantus SoloStar, NovoRapid FlexPen
Novo Nordisk A/S, Novo Nordisk A/S
Diabetes Mellitus, Type 2 2-es típusú diabétesz mellitus, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2021-004392-13: A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetes SUSTAIN OPTIMIZE - Klinické skúšanie, ktoré skúma ako účinkuje semaglutid pridaný k zníženej dávke inzulínu glargínu a porovnáva ho so samotným inzulínom glargínom vo vyššej dávke u ľudí s cukrovkou 2. typu

Ongoing
3
568
Europe
Semaglutide B 2.68 mg/ml PDS290, [Semaglutide], [N/A], Solution for injection, Lantus SoloStar, Ozempic
Novo Nordisk A/S, NOVO NORDISK. S.P.A., Novo Nordisk A/S
Diabetes Mellitus, type 2, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04460326: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Completed
3
137
US
Insulin glargine, Lantus®, NovoLog, NovoLog®, Insulin Fiasp, Fiasp®, Standard carbohydrate diet
Boston Medical Center, Novo Nordisk A/S
Type 2 Diabetes Treated With Insulin
05/23
05/23
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
09/24
04/25

Download Options